Published in Antivir Ther on January 01, 2010
Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med (2013) 2.49
Late HIV diagnosis: Differences by rural/urban residence, Florida, 2007-2011. AIDS Patient Care STDS (2014) 1.05
Engaging new migrants in infectious disease screening: a qualitative semi-structured interview study of UK migrant community health-care leads. PLoS One (2014) 0.98
Late entry into HIV care: lessons from Brazil, 2003 to 2006. BMC Infect Dis (2012) 0.98
Preferred HIV testing services and programme characteristics among clients of a rapid HIV testing programme. BMC Public Health (2013) 0.78
Late Presentation of HIV Infection: Prevalence, Trends, and the Role of HIV Testing Strategies in Guangzhou, China, 2008-2013. Biomed Res Int (2016) 0.78
Update on HIV in Western Europe. Curr HIV/AIDS Rep (2014) 0.77
Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med (2007) 6.30
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med (2003) 4.19
Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis (2010) 3.37
Syphilis and human immunodeficiency virus (HIV)-1 coinfection: influence on CD4 T-cell count, HIV-1 viral load, and treatment response. Sex Transm Dis (2006) 2.90
Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis (2009) 2.73
Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis (2007) 2.69
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS (2007) 2.58
The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS (2010) 2.51
Time to act: global apathy towards HIV/AIDS is a crime against humanity. Lancet (2002) 2.44
Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis (2012) 2.39
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med (2012) 2.24
Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria. AIDS (2013) 2.17
Whither or wither microbicides? Science (2008) 2.17
The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J Clin Invest (2008) 2.12
Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis (2004) 2.02
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr (2005) 1.87
Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nat Immunol (2009) 1.83
The development of artificial neural networks to predict virological response to combination HIV therapy. Antivir Ther (2007) 1.71
Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med (2002) 1.70
Mortality in siblings of patients coinfected with HIV and hepatitis C virus. J Infect Dis (2006) 1.68
A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. Clin Infect Dis (2005) 1.62
Risk of cerebrovascular events in persons with and without HIV: a Danish nationwide population-based cohort study. AIDS (2011) 1.57
HIV-1 continues to replicate and evolve in patients with natural control of HIV infection. J Virol (2010) 1.57
Schistosomiasis and HIV-1 infection in rural Zimbabwe: effect of treatment of schistosomiasis on CD4 cell count and plasma HIV-1 RNA load. J Infect Dis (2005) 1.56
Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment. Clin Infect Dis (2005) 1.52
Expression of fibroblast growth factor-21 in muscle is associated with lipodystrophy, insulin resistance and lipid disturbances in patients with HIV. PLoS One (2013) 1.50
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr (2005) 1.50
Routine HIV screening in France: clinical impact and cost-effectiveness. PLoS One (2010) 1.46
Right and left ventricular cardiac function in a developed world population with human immunodeficiency virus studied with radionuclide ventriculography. Am Heart J (2004) 1.46
Improved survival in HIV-infected persons: consequences and perspectives. J Antimicrob Chemother (2007) 1.45
Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir Ther (2005) 1.45
Incidence of low and high-energy fractures in persons with and without HIV infection: a Danish population-based cohort study. AIDS (2012) 1.45
K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antivir Ther (2003) 1.42
Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study. PLoS One (2011) 1.42
Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS (2003) 1.41
Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions. Clin Dev Immunol (2012) 1.39
Incidence and impact on mortality of severe neurocognitive disorders in persons with and without HIV infection: a Danish nationwide cohort study. Clin Infect Dis (2011) 1.37
Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis (2006) 1.35
A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy. Artif Intell Med (2009) 1.31
Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs. AIDS (2005) 1.28
Late entry to HIV care limits the impact of anti-retroviral therapy in The Netherlands. PLoS One (2008) 1.27
Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. J Infect Dis (2003) 1.25
Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Clin Infect Dis (2014) 1.25
Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. AIDS (2010) 1.23
Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving highly active antiretroviral therapy. J Infect Dis (2004) 1.22
High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients. J Acquir Immune Defic Syndr (2005) 1.21
Viral load levels measured at set-point have risen over the last decade of the HIV epidemic in the Netherlands. PLoS One (2009) 1.20
Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study. Clin Infect Dis (2005) 1.19
A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial. Antivir Ther (2005) 1.18
Predictors of mortality in a cohort of HIV-1-infected adults in rural Africa. J Acquir Immune Defic Syndr (2007) 1.17
Late presenters, repeated testing, and missed opportunities in a Danish nationwide HIV cohort. Scand J Infect Dis (2011) 1.17
Hospitalization for pneumonia among individuals with and without HIV infection, 1995-2007: a Danish population-based, nationwide cohort study. Clin Infect Dis (2008) 1.14
Induction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes. AIDS (2009) 1.12
The incidence rate of HIV type-1 drug resistance in patients on antiretroviral therapy: a nationwide population-based Danish cohort study 1999-2005. Antivir Ther (2009) 1.12
Reduced mortality and CD4 cell loss among carriers of the interleukin-10 -1082G allele in a Zimbabwean cohort of HIV-1-infected adults. AIDS (2007) 1.11
Retention in a public healthcare system with free access to treatment: a Danish nationwide HIV cohort study. AIDS (2012) 1.10
Risk of diabetes mellitus in persons with and without HIV: a Danish nationwide population-based cohort study. PLoS One (2012) 1.08
The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors. AIDS (2007) 1.07
Declining risk of triple-class antiretroviral drug failure in Danish HIV-infected individuals. AIDS (2005) 1.06
Failure to detect a non-B HIV-1 subtype by the HIV-1 Amplicor Monitor test, version 1.5: a case of unexpected vertical transmission. AIDS (2003) 1.06
Positive selection pressure introduces secondary mutations at Gag cleavage sites in human immunodeficiency virus type 1 harboring major protease resistance mutations. J Virol (2009) 1.05
Risk of cancer among HIV-infected individuals compared to the background population: impact of smoking and HIV. AIDS (2014) 1.05
Controlling the HIV epidemic with antiretrovirals: IAPAC consensus statement on treatment as prevention and preexposure prophylaxis. J Int Assoc Provid AIDS Care (2013) 1.04
Investigating signs of recent evolution in the pool of proviral HIV type 1 DNA during years of successful HAART. AIDS Res Hum Retroviruses (2007) 1.04
Patients' answers to simple questions about treatment satisfaction and adherence and depression are associated with failure of HAART: a cross-sectional survey. AIDS Patient Care STDS (2005) 1.02
Schistosomiasis and HIV in rural Zimbabwe: efficacy of treatment of schistosomiasis in individuals with HIV coinfection. Clin Infect Dis (2006) 1.02
Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients. J Acquir Immune Defic Syndr (2004) 1.02
Addressing the fear and consequences of stigmatization - a necessary step towards making HAART accessible to women in Tanzania: a qualitative study. AIDS Res Ther (2011) 1.02
Declining prevalence of HIV-infected individuals at risk of transmitting drug-resistant HIV in Denmark during 1997-2004. Antivir Ther (2006) 1.02
Autonomic dysfunction in HIV patients on antiretroviral therapy: studies of heart rate variability. Clin Physiol Funct Imaging (2007) 1.01
Statin therapy and mortality in HIV-infected individuals; a Danish nationwide population-based cohort study. PLoS One (2013) 1.01
Persistent inflammation and endothelial activation in HIV-1 infected patients after 12 years of antiretroviral therapy. PLoS One (2013) 1.00
Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. AIDS (2003) 0.99
Molecular phylogenetics of transmitted drug resistance in newly diagnosed HIV Type 1 individuals in Denmark: a nation-wide study. AIDS Res Hum Retroviruses (2011) 0.99
Early infant diagnosis of HIV in three regions in Tanzania; successes and challenges. BMC Public Health (2013) 0.99
Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy. Antivir Ther (2004) 0.99
Microbial translocation in HIV infection is associated with dyslipidemia, insulin resistance, and risk of myocardial infarction. J Acquir Immune Defic Syndr (2013) 0.99
Impact of injecting drug use on mortality in Danish HIV-infected patients: a nation-wide population-based cohort study. Addiction (2010) 0.98
Long-term mortality in HIV patients virally suppressed for more than three years with incomplete CD4 recovery: a cohort study. BMC Infect Dis (2010) 0.98
Changes in lung function of HIV-infected patients: a 4.5-year follow-up study. Clin Physiol Funct Imaging (2012) 0.98
Lung cancer in HIV patients and their parents: a Danish cohort study. BMC Cancer (2011) 0.98
Stable incidence of HIV diagnoses among Danish MSM despite increased engagement in unsafe sex. J Acquir Immune Defic Syndr (2012) 0.97
T-cell subset distribution in HIV-1-infected patients after 12 years of treatment-induced viremic suppression. J Acquir Immune Defic Syndr (2012) 0.97
Persisting inflammation and chronic immune activation but intact cognitive function in HIV-infected patients after long-term treatment with combination antiretroviral therapy. J Acquir Immune Defic Syndr (2013) 0.96
Physicians' communication with patients about adherence to HIV medication in San Francisco and Copenhagen: a qualitative study using Grounded Theory. BMC Health Serv Res (2006) 0.96
Implementation and effect of intensified case finding on diagnosis of tuberculosis in a large urban HIV clinic in Uganda: a retrospective cohort study. BMC Public Health (2012) 0.95
APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete "all or nothing" phenomenon. PLoS Genet (2012) 0.95
Introduction of HIV type 1 into an isolated population: molecular epidemiologic study from Greenland. AIDS Res Hum Retroviruses (2007) 0.95
Impact of injecting drug use on response to highly active antiretroviral treatment in HIV-1-infected patients: a nationwide population-based cohort study. Scand J Infect Dis (2010) 0.95
Reduction in coronary and peripheral vasomotor function in patients with HIV after initiation of antiretroviral therapy: a longitudinal study with positron emission tomography and flow-mediated dilation. Nucl Med Commun (2010) 0.95
Plasma cytokine levels in Tanzanian HIV-1-infected adults and the effect of antiretroviral treatment. J Acquir Immune Defic Syndr (2009) 0.94
Inpatient admissions and outpatient visits in persons with and without HIV infection in Denmark, 1995-2007. AIDS (2010) 0.94
NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected, ART-treated HIV patients. Eur J Immunol (2012) 0.94
Unmeasured confounding caused slightly better response to HAART within than outside a randomized controlled trial. J Clin Epidemiol (2007) 0.94
Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors. AIDS (2003) 0.93
Renal function and incidence of chronic kidney disease in HIV patients: a Danish cohort study. Scand J Infect Dis (2012) 0.93
Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. J Antimicrob Chemother (2003) 0.93